Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$101.93M+229210.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph Todisco
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 191
- Beta
- 1.50
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.27
Financials
Revenue
$101.93M+229210.9%Net Income
$25.99MEBITDA
$57.39MFree Cash Flow
$86.97MEPS (diluted)
$0.29Shares Outstanding (diluted)
92.48M+1084.0%Operating Expenses
$34.22MCash & Debt
$256.69MReturn of Capital
$11.09MRevenue by Segment (annual)
$304.34MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $311.71M | $163.06M | $2.25 |
| 2024 | $43.47M | $-17.93M | $-0.30 |
| 2023 | $0.00 | $-46.34M | $-0.91 |
| 2022 | $65.4K | $-29.70M | $-0.74 |
| 2021 | $190.9K | $-28.21M | $-0.75 |
| 2020 | $239.2K | $-22.03M | $-0.77 |
| 2019 | $283.3K | $-16.43M | $-0.68 |
| 2018 | $429.8K | $-26.83M | $-1.51 |
| 2017 | $329.3K | $-33.01M | $-2.99 |
| 2016 | $224.1K | $-24.64M | $-3.25 |
| 2015 | $210.1K | $-18.19M | $-2.90 |
| 2014 | $189.3K | $-20.45M | $-4.77 |
| 2013 | $2.0K | $-9.13M | $-3.30 |
| 2012 | $0.00 | $-3.43M | $-1.50 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.33
- Implied price
- $16.63
- Return from $7.19
- 18.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.27 — today's price is already 13.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 1 | 3 | 5 | 7 | 9 |
|---|---|---|---|---|---|
| -2.0% | -22.2% | -3.1% | 7.3% | 14.8% | 20.7% |
| 3.0% | -18.3% | 1.8% | 12.8% | 20.6% | 26.9% |
| 8.0% | -14.3% | 6.8% | 18.3% | 26.5% | 33.0% |
| 13.0% | -10.3% | 11.7% | 23.7% | 32.3% | 39.2% |
| 18.0% | -6.4% | 16.7% | 29.2% | 38.2% | 45.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-69.70%Social Signal Score
Mentions (8)
- Newszacks.com·28d ago·Neutral
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on Septem…
View source ↗ - Newszacks.com·35d ago·Positive
CorMedix (CRMD) Upgraded to Buy: Here's Why CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·52d ago·Positive
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Positive
CorMedix Q2 Earnings Call Highlights CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, giving it supply agreements with each of the five largest U.S. dialysis providers.
View source ↗ - Newszacks.com·53d ago·Positive
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.10 per share
Typical surprise +21.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.29 vs $0.24beat
- Thu, May 14$0.43 vs $0.35beat
- Thu, Mar 5$0.18 vs $0.86miss
- Wed, Nov 12$0.57 vs $0.48beat
- Thu, Aug 7$0.28 vs $0.20beat
- Tue, May 6$0.30 vs $0.25beat
Estimates and results for CRMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRMD officers and directors.
- Bought
- $276k
- Sold
- $4.8m
1 trade
14 trades
- Dillione Janetsold
- Dunton Alan Wsold
- Todisco Josephsold
- Dillione Janetsold
- Lefkowitz Steven Wsold
- Dillione Janetsold
- Dillione Janetsold
- Dillione Janetsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CRMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.